アブストラクト
| Title | 副作用対策 - 悪心・嘔吐, 眠気, せん妄 |
|---|---|
| Subtitle | 特集 新ガイドラインでこう変わった! がん疼痛治療薬の新しい使い方 |
| Authors | 深澤義輝 |
| Authors (kana) | |
| Organization | 埼玉県立がんセンター緩和ケア科 |
| Journal | 月刊薬事 |
| Volume | 63 |
| Number | 1 |
| Page | 45-49 |
| Year/Month | 2021 / 1 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | [Points] ●オピオイド鎮痛薬の副作用をマネジメントするうえで, オピオイド以外の原因がないか評価することが重要である. ●悪心・嘔吐はオピオイド開始・増量時に生じやすい. 耐性により症状が軽減するまでの間, 制吐薬を中心に対応する. 制吐薬の予防的投与は推奨されていない. ●眠気, せん妄が生じた際には, オピオイドが過量になっていないか注意する. 必要に応じて, オピオイドの減量やスイッチングを検討する. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) McNicol E, et al: Management of opioid side effects in cancer-related and chronic noncancer pain; a systematic review. J Pain, 4:231-256, 2003
- 2) 日本緩和医療学会ガイドライン統括委員会・編:がん疼痛の薬物療法に関するガイドライン 2020年版.金原出版, 2020
- 3) Kim SW, et al: Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. Psychiatry Clin Neurosci, 62:75-83, 2008
- 4) Caraceni A, et al: Use of opioid analgesics in the treatment of cancer pain; evidence-based recommendations from the EAPC. Lancet Oncol, 13:e58-68, 2012
- 5) National Comprehensive Cancer Network: Adult Cancer Pain, Version 1. 2018, NCCN Clinical Practice Guidelines in Oncology, 2018
残りの16件を表示する
- 6) Larkin PJ, et al: Diagnosis, assessment and management of constipation in advancer cancer; ESMO clinical practice guidelines. Ann Oncol, 29:iv111-iv125, 2018
- 7) Tsukuura H, et al: Efficacy of prophylactic treatment for oxycodone-induced nausea and vomiting among patients with cancer pain (POINT); a randomized, placebo-controlled, double-blind trial. Oncologist, 23:367-374, 2018
- 8) Lawlor PG, et al: Occurrence, causes, and outcome of delirium in patients with advanced cancer; a prospective study. Arch Intern Med, 160:786-794, 2000
- 9) Bruera E, et al: Impact of delirium and recall on the level of distress in patients with advanced cancer and their family caregivers. Cancer, 115:2004-2012, 2009
- 10) Morita T, et al: Opioid rotation from morphine to fentanyl in delirious cancer patients; an open-label trial. J Pain Symptom Manage, 30:96-103, 2005
- 11) Maddocks I, et al: Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. J Pain Symptom Manage, 12:182-189, 1996
- 12) Lee MA, et al: Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat Med, 15:26-34, 2001
- 13) Moryl N, et al: Methadone in the treatment of pain and terminal delirium in advanced cancer patients. Palliat Support Care, 3:311-317, 2005
- 14) Neufeld KJ, et al: Antipsychotic medication for prevention and treatment of delirium in hospitalized adults;a systematic review and meta-analysis. J Am Geriatr Soc, 64:705-714, 2016
- 15) Agar MR, et al: Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care;a randomized clinical trial. JAMA Intern Med, 177:34-42, 2017
- 16) Leucht S, et al: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia; a multiple-treatments meta-analysis. Lancet, 382:951-962, 2013
- 17) 日本サイコオンコロジー学会,他・編:がん患者におけるせん妄ガイドライン 2019年版.金原出版, 2019
- 18) Breitbart W, et al: A double-blind trial of haloperidol, chlorpromazine and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry, 153:231-237, 1996
- 19) Gaudreau JD, et al: Psychoactive medications and risk of delirium in hospitalized cancer patients. J Clin Oncol, 23:6712-6718, 2005
- 20) Hui D, et al: Effect of lorazepam with haloperidol vs haloperidol alone on agitated delirium in patients with advanced cancer receiving palliative care; a randomized clinical trial. JAMA, 31:1047-1056, 2017
- 21) Hshieh TT, et al: Effectiveness of multicomponent non-pharmacological delirium interventions; a meta-analysis. JAMA Intern Med, 175:512-520, 2015
